U.S. Food and Drug Administration

government_agency

Last mentioned: Feb 23, 2026

Timeline

  1. Expedited Pathway Formalized

    FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.

  2. START Pilot Launch

    FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.

  3. CBER Reorganization

    The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.

  4. Luxturna Approval

    FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.

Stories mentioning U.S. Food and Drug Administration 1

regulation Bullish

FDA Accelerates Gene Therapy Approvals via New Regulatory Framework

The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.

8 sources